Apomorphine effect on pain threshold in Parkinson's disease: A clinical and positron emission tomography study

Movement Disorders

Volumn 26, Issue 1, 2011, Pages 153-157

  Dellapina, Estelle ^a,b   Gerdelat Mas, Angélique ^c   Ory Magne, Fabienne ^c   Pourcel, Laure ^b   Galitzky, Monique ^d   Calvas, Fabienne ^d   Simonetta Moreau, Marion ^a,b,c   Thalamas, Claire ^d   Payoux, Pierre ^a,b   Brefel Courbon, Christine ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d CHU PURPAN   (France)

Author keywords

Apomorphine; H215O positron emission tomography; Pain threshold; Parkinson's disease

Indexed keywords

APOMORPHINE; PLACEBO;

ADULT; ARTICLE; CEREBELLUM; CLINICAL ARTICLE; CLINICAL STUDY; CROSSOVER PROCEDURE; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROENCEPHALOGRAM; FEMALE; FLEXOR REFLEX; HUMAN; INSULA; MALE; MONOAMINERGIC SYSTEM; NOCICEPTIVE STIMULATION; PAIN THRESHOLD; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROCESSING; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTARY MOTOR AREA; THALAMUS NUCLEUS; THERMAL STIMULATION;

AGED; ANTIPARKINSON AGENTS; APOMORPHINE; CEREBRAL CORTEX; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURALGIA; OXYGEN ISOTOPES; PAIN THRESHOLD; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY;

EID: 79951489834     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23406     Document Type: Article

References (23)

1. Beiske AG, Loge JH, Ronningen A, Svensson E. Pain in Parkinson's disease: prevalence and characteristics. Pain 2009; 141: 173-177.
2. Brefel-Courbon C, Grolleau S, Thalamas C, et al. Comparison of chronic analgesic drugs prevalence in Parkinson's disease, other chronic diseases and the general population. Pain 2009; 141: 14-18.
3. Brefel-Courbon C, Payoux P, Thalamas C, et al. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 2005; 20: 1557-1563.
4. Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, et al. Levodopa raises objective pain threshold in Parkinson's disease: a RIII reflex study. J Neurol Neurosurg Psychiatry 2007; 78: 1140-1142.
5. Mylius V, Engau I, Teepker M, et al. Pain sensitivity and descending inhibition of pain in Parkinson's disease. J Neurol Neurosurg Psychiatry 2009; 80: 24-28.
6. Slaoui T, Mas-Gerdelat A, Ory-Magne F, Rascol O, Brefel-Courbon C. [Levodopa modifies pain thresholds in Parkinson's disease patients]. Rev Neurol (Paris) 2007; 163: 66-71.
7. Dolphin A, Jenner P, Marsden CD. Noradrenaline synthesis from L-DOPA in rodents and its relationship to motor activity. Pharmacol Biochem Behav 1976; 5: 431-439.
8. Pertovaara A. Noradrenergic pain modulation. Prog Neurobiol 2006; 80: 53-83.
9. Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005; 114: 29-36.
10. Fruhstorfer H, Lindblom U, Schmidt WC. Method for quantitative estimation of thermal thresholds in patients. J Neurol Neurosurg Psychiatry 1976; 39: 1071-1075.
11. Defrin R, Pick CG, Peretz C, Carmeli E. A quantitative somatosensory testing of pain threshold in individuals with mental retardation. Pain 2004; 108: 58-66.
12. Willer JC. Comparative study of perceived pain and nociceptive flexion reflex in man. Pain 1977; 3: 69-80.
13. Brix G, Zaers J, Adam LE, et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med 1997; 38: 1614-1623.
14. Djaldetti R, Shifrin A, Rogowski Z, Sprecher E, Melamed E, Yarnitsky D. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology 2004; 62: 2171-2175.
15. Vase L, Robinson ME, Verne GN, Price DD. The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients. An empirical investigation. Pain 2003; 105: 17-25.
16. Hudson AJ. Pain perception and response: central nervous system mechanisms. Can J Neurol Sci 2000; 27: 2-16.
17. Laurent B, Peyron R, Garcia Larrea L, Mauguiere F. [Positron emission tomography to study central pain integration]. Rev Neurol (Paris) 2000; 156: 341-351.
18. Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007; 130: 1819-1833.
19. Braak H, Sastre M, Bohl JR, de Vos RA, Del Tredici K. Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol 2007; 113: 421-429.
20. Brefel-Courbon C, Thalamas C, Peyro Saint Paul H, Senard JM, Montastruc JL, Rascol O. Alpha2-adrenoceptor antagonists: a new approach to Parkinson's disease. CNS drugs 1998; 10: 189-207.
21. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 1998; 51: S2-S9.
22. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318: 121-134.
23. Djaldetti R, Yust-Katz S, Kolianov V, Melamed E, Dabby R. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol 2007; 30: 201-205.